Fast Track designation and strong Phase 2 extension data de-risk the upcoming Phase 3 LEGACY trial. Monitor Q4 2026 for trial initiation and enrollment updates; positive Phase 3 data could be transformative for this early-stage biotech.
Price Chart
Executive Summary
Eledon Pharmaceuticals announced FDA Fast Track designation for tegoprubart in kidney transplantation and presented positive Phase 2 BESTOW extension data showing statistically significant eGFR advantage (71 vs 58 mL/min/1.73 m² at month 24) and zero rejections beyond six months in the tegoprubart arm versus seven in tacrolimus. The company plans to initiate the Phase 3 LEGACY trial in Q4 2026, enrolling ~600 patients.
Key Facts
- FDA granted Fast Track designation for tegoprubart in prevention of kidney transplant rejection
- Phase 2 BESTOW extension: tegoprubart patients maintained ~13 mL/min/1.73 m² higher eGFR vs tacrolimus at month 24 (71 vs 58, p<0.05)
- Zero biopsy-proven acute rejections in tegoprubart arm beyond six months vs seven in tacrolimus arm
- Phase 3 LEGACY trial expected to initiate in Q4 2026, enrolling ~600 patients with primary endpoint of non-inferiority on composite of BPAR, graft loss, and death
Financial Impact
Fast Track designation accelerates regulatory pathway and reduces development risk; positive Phase 2 data supports Phase 3 initiation, likely increasing probability of approval and commercial value of tegoprubart in kidney transplantation
Risk Factors
- Phase 3 LEGACY trial may fail to meet primary endpoint or show non-inferiority
- Company may require additional financing to complete Phase 3 trial
- Competitive landscape includes established immunosuppressants like tacrolimus and emerging anti-CD40L agents
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3366123 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $2.89 $2.26 | ▼ −21.97% | ▼ −21.41% | $2.28 (−21.28%) |
Sep 22, 2026 5w ago | Press Release | $2.89 $2.26 | ▼ −21.97% | ▼ −21.41% | $2.28 (−21.28%) |
May 20, 2026 22w ago | Press Release | $3.89 $3.82 | ▼ −1.93% | ▼ −2.26% | $2.28 (−41.52%) |
Mar 10, 2026 33w ago | Press Release | $2.90 $3.13 | ▲ +7.93% | ▲ +8.09% | $2.28 (−21.55%) |
Feb 28, 2026 34w ago | Institutional Cluster | $2.66 $2.71 | ▲ +1.88% | ▲ +9.82% | $2.28 (−14.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers